A Multi-Center, Two-Stage, Open-Label, Prospective, Fellow-Eye Active-Comparator-Controlled Phase 2a Study of ENV515 (Travoprost) Intracameral Implant in Subjects With Bilateral Ocular Hypertension or Early Primary Open-Angle Glaucoma

Trial Profile

A Multi-Center, Two-Stage, Open-Label, Prospective, Fellow-Eye Active-Comparator-Controlled Phase 2a Study of ENV515 (Travoprost) Intracameral Implant in Subjects With Bilateral Ocular Hypertension or Early Primary Open-Angle Glaucoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Travoprost (Primary)
  • Indications Open-angle glaucoma
  • Focus Therapeutic Use
  • Sponsors Envisia Therapeutics
  • Most Recent Events

    • 17 Aug 2017 Planned number of patients changed from 41 to 46.
    • 17 Aug 2017 Planned End Date changed from 31 Mar 2018 to 31 Oct 2018.
    • 17 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 2 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top